Ani Pharmaceuticals INC Form 4 insider transactions

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, sold shares of common stock on April 18 and 19, 2024, under a pre-arranged trading plan.

Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock between April 15 and April 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock on April 12, 2024, at a price of $67.79 per share.

ANI Pharmaceuticals SVP Marken James G. reports disposition of shares for tax purposes following vesting of restricted stock.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reported the disposal of 4,534 shares of common stock to cover tax obligations related to vesting restricted stock.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on April 1, 2024, at a weighted average price of $67.25.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reported the disposal of shares to cover tax obligations related to vesting restricted stock.

SVP of Operations and Product Development at ANI Pharmaceuticals, James G. Marken, reports disposition of shares for tax purposes following vesting of restricted stock.

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reported a transaction involving the withholding of shares for tax purposes related to the vesting of restricted stock.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock at $66.54 per share on March 13, 2024, under a pre-arranged 10b5-1 trading plan.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock at a weighted average price of $65.81 on March 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, sold 10,000 shares of common stock at an average price of $67.17 on March 8, 2024, under a pre-arranged trading plan.

Stephen Carey, SVP & CFO of ANI Pharmaceuticals, reported the disposition of shares to cover tax obligations and sales of common stock.

ANI Pharmaceuticals' CEO, Nikhil Lalwani, recently sold shares of the company's common stock in a series of transactions.

James G. Marken, SVP of Operations & Product Development at ANI Pharmaceuticals, sold 24,338 shares of common stock at an average price of $66.37 on March 7, 2024.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, reports the withholding of shares for tax purposes related to the vesting of restricted stock.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports the disposal of 2,110 shares for tax purposes following the vesting of restricted stock.

Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock over three days in March 2024 under a pre-arranged trading plan.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 5,000 shares of common stock at an average price of $66 on March 5, 2024.

Director Antonio R. Pera of ANI Pharmaceuticals sold 7,000 shares of common stock on March 4, 2024.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, disposed of shares to cover tax obligations related to vesting restricted stock.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.

SVP of Operations and Product Development at ANI Pharmaceuticals, James G. Marken, reports disposition of shares for tax purposes following vesting of restricted stock.

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, disposed of 10,014 shares of common stock to cover tax obligations related to vesting restricted stock.

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, disposed of shares to cover tax obligations related to the vesting of restricted stock.

Chad Gassert, SVP at ANI Pharmaceuticals, reports disposition of shares for tax purposes following vesting of restricted stock.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reports the disposition of 1,173 shares of common stock to cover tax obligations related to vesting restricted stock.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, reported a transaction involving the withholding of shares for tax purposes related to the vesting of restricted stock.